Medscape5d
FDA OKs Esketamine Nasal Spray Monotherapy for Resistant Depression
The expanded indication allows esketamine nasal spray to be used as a standalone treatment in adults with MDD who have not ...
Medindia1d
FDA Approves Esketamine Nasal Spray for Resistant Depression
FDA approves esketamine nasal spray as a standalone treatment for adults with treatment-resistant depression, offering rapid ...
Medical News Today2d
FDA-approved nasal spray for severe depression can lead to remission
The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...
Verywell Health on MSN1d
Spravato Nasal Spray Can Now Be Used Alone for Treatment-Resistant Depression
People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.
WebMD2d
What to Know About the New Nasal Spray for Tough Depression
CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more ...
BioSpace19h
Atai Touts Positive Data for Psychedelic Therapy in Alcohol Use Disorder
The results, which come on the heels of the FDA’s approval of J&J’s esketamine nasal spray Spravato as a monotherapy for ...
ScienceAlert on MSN6d
FDA-Approved Nasal Spray For Depression Is First Of Its Kind
A ketamine-based nasal spray is officially the first and only standalone therapy available for treatment-resistant depression ...
Renal & Urology News2d
FDA Approves Spravato Nasal Spray for Treatment-Resistant Depression
(HealthDay News) — The US Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major depressive disorder who have had an inadequate response to at ...
A first of its kind: US FDA-approved nasal spray available for treatment-resistant depression in America
Johnson & Johnson reported that Spravato treated over 100,000 patients in 77 countries worldwide, including roughly 80,000 in ...